David Mead
Chief Executive Officer
Dr. Mead holds a Ph.D. in physiology from the University of Illinois, has over 80 publications, 9 patents, and has secured $30M in SBIR and related grants. With 30+ years in life sciences, his expertise spans molecular cloning, protein analysis, metagenomics, genomics, synthetic biology, and next-generation sequencing. Dr. Mead founded Lucigen in 1998, which was acquired for $70M in 2018. He invented TA cloning, the leading PCR amplicon cloning method with nearly $1B in lifetime sales.